Ironwood Pharmaceuticals Reports Q3 Earnings Beat and Raises Full-Year Revenue Guidance
Ironwood Pharmaceuticals (IRWD) reported third-quarter financial results that exceeded analyst expectations, posting a Non-GAAP EPS of $0.36, which beat estimates by $0.05. The company's revenue reached $133.04 million, representing a 9.0% increase year-over-year and surpassing consensus estimates by $11.47 million. Driven by strong performance, the company raised its full-year 2026 guidance for LINZESS (linaclotide) U.S. net sales to a range of $1.20 billion to $1.25 billion, marking an expected year-over-year increase of more than 35%. Consequently, Ironwood has also upwardly revised its total revenue guidance for the full year.
Tickers: $IRWD
Topics: earnings report guidance raise linaclotide revenue growth